Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma
Authors:
- 11 November 2022
- journal article
- editorial
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (3) , 943-945.e2
Abstract
No abstract availableFunding Information
- Amgen
- AstraZeneca
This publication has 6 references indexed in Scilit:
- Tezepelumab in Adults and Adolescents with Severe, Uncontrolled AsthmaNew England Journal of Medicine, 2021
- Relative efficacy and safety of inhaled corticosteroids in patients with asthmaAnnals of Allergy, Asthma & Immunology, 2020
- Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthmaExpert Opinion on Therapeutic Targets, 2020
- Tezepelumab in Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2017
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Significant variability in response to inhaled corticosteroids for persistent asthmaJournal of Allergy and Clinical Immunology, 2002